Literature DB >> 9707506

A pharmacodynamic analysis of TCDD-induced cytochrome P450 gene expression in multiple tissues: dose- and time-dependent effects.

M J Santostefano1, X Wang, V M Richardson, D G Ross, M J DeVito, L S Birnbaum.   

Abstract

The ability of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) to alter gene expression and the demonstration that the induction of CYP1A2 is responsible for hepatic TCDD sequestration suggest that both pharmacokinetic and pharmacodynamic events must be incorporated for a quantitative description of TCDD disposition. In this paper, a biologically based pharmacodynamic (BBPD) model for TCDD-induced biochemical responses in multiple tissues was developed. The parameters responsible for tissue response were estimated simultaneously with a refined physiologically based pharmacokinetic (PBPK) model developed by Wang et al. (1997a), by using the time-dependent effects of TCDD on induced CYP1A1/CYP1A2 gene expression in multiple target tissues (liver, lungs, kidneys, and skin) of female Sprague-Dawley rats treated with 10 microgram TCDD/kg for 30 min, 1, 3, 8, or 24 h, or 7, 14, or 35 days. This refined BBPD model developed based on the time-course of TCDD-induced CYP1A1/CYP1A2 protein expression, and associated enzymatic activities well described the dose-dependent effects of TCDD on cytochrome P450 protein expression and associated enzyme activities in the multiple tissues of female Sprague-Dawley rats at 3 days following a single exposure to TCDD (0.01-30.0 micromgram TCDD/kg). This is the first BBPD model to quantitatively describe the time- and dose-dependent effects of TCDD on induced CYP1A1/CYP1A2 protein expression and associated enzyme activities in multiple target tissues for TCDD-induced biochemical responses. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707506     DOI: 10.1006/taap.1998.8466

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  5 in total

1.  Induction of oxidative stress responses by dioxin and other ligands of the aryl hydrocarbon receptor.

Authors:  John F Reichard; Timothy P Dalton; Howard G Shertzer; Alvaro Puga
Journal:  Dose Response       Date:  2006-05-01       Impact factor: 2.658

2.  Immunomodulation By Subchronic Low Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.

Authors:  Eun-Ju Yang; John V Stokes; Evangel Kummari; Jeffrey Eells; Barbara L F Kaplan
Journal:  Toxicol Sci       Date:  2016-01-27       Impact factor: 4.849

3.  Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD.

Authors:  Claude Emond; Linda S Birnbaum; Michael J DeVito
Journal:  Environ Health Perspect       Date:  2006-09       Impact factor: 9.031

4.  Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.

Authors:  Y Kapelyukh; C J Henderson; N Scheer; A Rode; C R Wolf
Journal:  Drug Metab Dispos       Date:  2019-05-30       Impact factor: 3.922

5.  Progesterone receptor membrane component 1 is involved in oral cancer cell metastasis.

Authors:  Hsun-Yu Huang; Hsiu-Chuan Chou; Ching-Hsuan Law; Wan-Ting Chang; Tzu-Ning Wen; En-Chi Liao; Meng-Wei Lin; Li-Hsun Lin; Yu-Shan Wei; Yi-Ting Tsai; Hsin-Yi Chen; Kui-Thong Tan; Wen-Hung Kuo; Mei-Lan Ko; Shing-Jyh Chang; Ying-Ray Lee; Hong-Lin Chan
Journal:  J Cell Mol Med       Date:  2020-07-16       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.